Sofinicline

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSofinicline
Drug Alias Namesofiniclina索非克兰sofiniclinum苏非克兰ABT-894 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinic acetylcholine receptor alpha4/beta2/alpha5 agonists
TargetsNicotinic acetylcholine receptor alpha4/beta2/alpha5
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsAttention Deficit Disorder with HyperactivityDiabetic Neuropathies

Other Information

ATC CodeN/A
Related LinksN/A